Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Pelican Therapeutics Inc
Profile last edited on: 10/21/21      CAGE: 88WK8      UEI: FZ4MXCJNNE23

Business Identifier: immuno-oncology
Year Founded
2012
First Award
2020
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

8122 Datapoint Drive Suite 445
San Antonio, TX 78229
Location: Single
Congr. District: 20
County: Bexar

Public Profile

Pelican Therapeutics Inc, spun out of SBIR firm Heat Biologics in 2012 and then acquired by Heat Biologics in 2017 and now operating as a subsidiary of Heat Biologics, develops immunotherapeutics for the stimulation of CD8+ T cells for cancer treatment. The company's two primary product candidates are both T cell activation therapeutics, PTX-35 and PTX-45, and have achieved in vivo regulatory T cell expansion in humans.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$224,713
Phase II Dollars
$0
Total Awarded
$224,713

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $224,713
Project Title: Application of TNFRSF25 Agonists for Prophylaxis and Treatment of Graft Versus Host Disease

Key People / Management

  Rahul Jasuja -- CEO

  George Peoples -- Chief Medical Officer

  Carl Seavey

  Matthew Seavey -- Vice President of Research

  Gary Vinson -- Vice President of Chemistry and Manufacturing Controls

  David Wilson

Company News

May 02 2017
Heat Bio completes acquisition of Texas company
Mar 08 2017
Durham outfit to acquire Texas company in a cash-stock deal
May 19 2016
Pelican Therapeutics awarded $15.2 million to develop novel immune therapy for multiple cancers